Skip to main content

Advertisement

SpringerLink
Log in

1α,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cellsin vitro

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Using the Boyden chamber invasion assay, the effect of 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] on the invasiveness of the highly invasive, oestrogen receptor-negative human breast cancer cell line MDA-MB-231 was examined. The MDA-MB-231 cells were shown to contain high-affinity receptors for 1α,25(OH)2D3 with a Kd of 1.5 × 10−11 M. When the cells were treated with 1α,25(OH)2D3 for 4 days before the assay was performed, a dose-dependent inhibition of their invasive potential was demonstrated. Fifty per cent inhibition of invasion was obtained with a concentration of 13 pM of 1α,25(OH)2D3. However, when the cells were treated for only 6 h during the assay, no inhibitory effect was seen. The process of migration was also affected by treatment with 1α,25(OH)2D3 for 4 days, although the inhibition was not of the same magnitude as seen for the invasion. Fifty per cent inhibition of migration occurred at a concentration of 3.2 nM of 1α,25(OH)2D3 (250 times higher than in the invasion assay). Inhibition of invasion and migration was not due to the known anti-proliferative effect of 1α,25(OH)2D3, as no growth reduction could be demonstrated with treatment up to 5 days. Based on the present investigation it can therefore be concluded that 1α,25(OH)2D3 is able to inhibit tumour cell invasiveness by a mechanism which is not exclusively based on its anti-proliferative and anti-migrative effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liotta LA, 1986, Tumor invasion and metastasis-role of the extracellular matrix. Rhoads Memorial Award Lecture.Cancer Res,46, 1–7.

    Google Scholar 

  2. Abe J, Nakano T, Nishii Y,et al. 1991, A novel D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancerin vitro andin vivo without causing hypercalcemia.Endocrinology,129, 832–7.

    Google Scholar 

  3. Chouvet C, Vicard E, Devonec M and Saez S, 1986, 1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20).J Steroid Biochem,24, 373–6.

    Google Scholar 

  4. Colston K, Colston MJ and Feldman D, 1981, 1,25-Dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture.Endocrinology,108, 1083–6.

    Google Scholar 

  5. Colston KW, Chander SK, MacKay AG and Coombes RC, 1992, Effects of synthetic vitamin D analogues on breast cancer cell proliferationin vivo andin vitro.Biochem Pharmacol,44, 693–702.

    Google Scholar 

  6. Dokoh S, Donaldson CA, Marion SL, Pike JW and Haussler MR, 1983, The ovary: a target organ for 1,25-dihydroxyvitamin D3.Endocrinology,112, 200–5.

    Google Scholar 

  7. Dokoh S, Donaldson CA and Haussler MR, 1984, Influence of 1,25-dihydroxyvitamin D3 on cultured osteogenic sarcoma cells: correlation with the 1,25-dihydroxyvitamin D3 receptor.Cancer Res,44, 2103–9.

    Google Scholar 

  8. Eisman JA, Koga M, Sutherland RL, Barkla DH and Tutton PJM, 1989, 1,25-Dihydroxyvitamin D3 and the regulation of human cancer cell replication.Soc Expl Biol Med,191, 221–6.

    Google Scholar 

  9. Frampton RJ, Omond SA and Eisman JA, 1983, Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites.Cancer Res,43, 4443–7.

    Google Scholar 

  10. Iino Y, Noritaka S, Maemura M,et al. 1992, 1α,25(OH)2D3, hypercalcaemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.Breast Cancer Res Treatment,22, 133–40.

    Google Scholar 

  11. Binderup L and Bramm E, 1988, Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiationin vitro and on calcium metabolismin vivo. Biochem Pharmacol,37, 889–95.

    Google Scholar 

  12. Koeffler HP, Hirji K, Itri L and the Southern California Leukemia Group, 1985, 1,25-Dihydroxyvitamin D3:in vivo andin vitro effects on human preleukemic and leukemic cells.Cancer Treatment Reports,69, 1399–407.

    Google Scholar 

  13. Norman AW, Zhou JY, Henry HL, Uskokovic MR and Koeffler HP, 1990, Structure-function studies on analogues of 1α,25-hydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption.Cancer Res,50, 6857–64.

    Google Scholar 

  14. Okabe-Kado J, Honma Y, Kasukabe T and Hozumi M, 1992, Synthesis of active metabolite(s) from 1α-hydroxyvitamin D3 by human monocytic leukemia cells.FEBS Lett,309, 399–401.

    Google Scholar 

  15. Studzinski GP, Bhandal AK and Brelvi ZS, 1985, Cell cycle sensitivity of HL-60 cells to the differentiation-inducing effects of 1α,dihydroxyvitamin D3.Cancer Res,45, 3898–905.

    Google Scholar 

  16. Colston K, Berger U and Coombes RC, 1989, Possible role for vitamin D in controlling breast cancer cell proliferation.Lancet,28, 188–91.

    Google Scholar 

  17. Colston K, Mackay AG, Chander S, Binderup L and Coombes RC, 1991, Novel vitamin D analogues suppress tumour growthin vivo. In: Norman AW, Bouillon R and Thomasset M, eds.Vitamin D: gene regulation, structure-function analysis and clinical application, pp. 465–6. Berlin: W. de Gruyter.

    Google Scholar 

  18. Honma Y, Hozumi M, Abe E,et al. 1983, 1α,25-Hydroxyvitamin D3 and 1α-hydroxyvitamin D3 prolong survival time in mice inoculated with myeloid leukemia cells.Proc Natl Acad Sci, USA,80, 201–4.

    Google Scholar 

  19. Oikawa T, Yoshida Y, Shimamura M,et al. 1991, Antitumor effect of 22-oxa-1α,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene.Anti-cancer Drugs,2, 475–80.

    Google Scholar 

  20. Sato K, Takusagawa K, Asoo N and Konno K, 1982, Antitumour effect of 1α-hydroxyvitamin D3.Tohoku J Exp Med,138, 445–6.

    Google Scholar 

  21. Sato T, Takusagawa K, Asoo N and Konno K, 1984, Effect of 1α-hydroxyvitamin D3 on metastasis of rat ascites hepatoma K-231.Br J Cancer,50, 123–5.

    Google Scholar 

  22. Berger U, McClelland RA, Wilson P,et al. 1991, Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis.Cancer Res,51, 239–44.

    Google Scholar 

  23. Thompson EW, Paik S, Brünner N, 1992, Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.J Cell Phys,150, 534–44.

    Google Scholar 

  24. Eisman JA, Suva LJ and Martin TJ, 1986, Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancers.Cancer Res,46, 5406–8.

    Google Scholar 

  25. Hall RE, Lee CSL, Alexander IE,et al. 1990, Steroid hormone receptor gene expression in human breast cancer cells: inverse relationship between oestrogen and glucocorticoid receptor messenger RNA levels.Int J Cancer,46, 1081–7.

    Google Scholar 

  26. Brünner N, Thompson EW, Spang-Thomsen M,et al. 1992,LacZ transduced human breast cancer xenografts as anin vivo model for the study of invasion and metastasis.Eur J Cancer,28A, 1989–95.

    Google Scholar 

  27. Price JE, Polyzos A, Zhang RD and Daniels LM, 1990, Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.Cancer Res,50, 717–21.

    Google Scholar 

  28. Brinkley BR, Beall PT, Wible LJ,et al. 1980, Variations in cell form and cytoskeleton in human breast carcinoma cellsin vitro.Cancer Res,40, 3118–29.

    Google Scholar 

  29. Frandsen TL, Boysen BB, Jirus S,et al. 1992,In vitro andin vivo assays for the study of human cancer cell invasion and metastasis.Fibrinolysis,6, supplement 4, 71–6.

    Google Scholar 

  30. Cho YL, Christensen C, Saunders DE,et al. 1991, Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells.Cancer Res,51, 2848–53.

    Google Scholar 

  31. Bower M, Colston KW, Stein RC,et al. 1991, Topical calcipotriol treatment in advanced breast cancer.Lancet,337, 701–2.

    Google Scholar 

  32. Findley DM, Michelangeli VP, Eisman JA,et al. 1980, Calcitonin and 1,25-dihydroxyvitamin D3 receptors in human breast cancer cell lines.Cancer Res,40, 4764–7.

    Google Scholar 

  33. Eisman JA, Martin TJ, MacIntyre I and Moseley JM, 1979, 1,25-Dihydroxyvitamin D receptors in breast cancer cells.Lancet,29, 1335–6.

    Google Scholar 

  34. Minghetti PP and Norman AW, 1988, 1,25(OH)2-Vitamin D3 receptors: gene regulation and genetic circuitry.FASEB J,2, 3043–53.

    Google Scholar 

  35. Binderup L, 1992, Immunological properties of vitamin D analogues and metabolites.Biochem Pharmacol,43, 1885–92.

    Google Scholar 

  36. Norman AW, Nemere I, Zhou LX,et al. 1992, 1,25(OH)2-Vitamin D3, a steroid hormone that produces biological effects via both genomic and non-genomic pathways.J Steroid Biochem Molec Biol,41, 231–40.

    Google Scholar 

  37. Barsky SH, Rao CN, Hyams D and Liotta LA, 1984, Characterization of a laminin receptor from human breast carcinoma tissue.Breast Cancer Res Treatment,4, 181–8.

    Google Scholar 

  38. Castronovo V, Taraboletti G, Liotta LA and Sobel ME, 1989, Modulation of laminin receptor expression by estrogen and progestins in human breast cancer cell lines.J Natl Cancer Inst,81, 781–8.

    Google Scholar 

  39. Horand Hand P, Thor A, Schlom J, Rao CN and Liotta L, 1985, Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody.Cancer Res,45, 2713–19.

    Google Scholar 

  40. Koli K and Keski-Oja J, 1993, Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes.J Invest Dermatol,101, 706–12.

    Google Scholar 

  41. Ossowski L, 1992, Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase.Cancer Res,52, 6754–60.

    Google Scholar 

  42. Pyke C, Græm N, Ralfkiær E,et al. 1993, Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.Cancer Res,53, 1911–15.

    Google Scholar 

  43. Liotta LA, Tryggvason K, Garbisa S,et al. 1980, Metastatic potential correlates with enzymatic degradation of basement membrane collagen.Nature,284, 67–8.

    Google Scholar 

  44. Nakajima M, Welch DR, Belloni PN and Nicholson GL, 1987, Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary carcinoma cell clones of differing metastatic potentials.Cancer Res,47, 4869–76.

    Google Scholar 

  45. Nakajima M, Lotan D, Baig MM,et al. 1989, Inhibition by retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells.Cancer Res,49, 1698–706.

    Google Scholar 

  46. Bar-Shavit Z, Kahn AJ, Stone KR,et al. 1986, Reversibility of vitamin D-induced human leukemia cell-line maturation.Endocrinology,118, 679–86.

    Google Scholar 

  47. Carlberg C, Bendik I, Wyss A,et al. 1993, Two nuclear signalling pathways for vitamin D.Nature,361, 657–60.

    Google Scholar 

  48. Clarke R, Brünner N, Thompson EW,et al. 1989, The inter-relationships between ovarian-independent growth, tumorigenicity, invasiveness and antieostrogen resistance in the malignant progression of human breast cancer.J Endocr,122, 331–40.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Leo Pharmaceutical Products, DK-2750, Ballerup, Denmark

    Christina Mørk Hansen, Thomas L. Frandsen, Nils Brünner & Lise Binderup

  2. Finsen Laboratory, Strandboulevarden 49, Copenhagen, Denmark

    Thomas L. Frandsen & Nils Brünner

Authors
  1. Christina Mørk Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas L. Frandsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nils Brünner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lise Binderup
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hansen, C.M., Frandsen, T.L., Brünner, N. et al. 1α,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cellsin vitro . Clin Exp Metast 12, 195–202 (1994). https://doi.org/10.1007/BF01753887

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01753887

Keywords

Search

Navigation